In the IMvigor011 trial, ctDNA-guided adjuvant atezolizumab reduced the risk of disease recurrence or death by 36% and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results